+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-11-28Number of Pages: 60

Prefilled Syringe Small Molecule Market (Therapeutic Class - Neurology Drug, Cardiovascular Drugs, Analgesics, and Adjuvants) - U.S. and EU-5 Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

U.S. and EU-5 Prefilled Syringe Small Molecule Market: Overview

The U.S. and EU-5 market for prefilled syringe small molecule is projected to register a remarkable growth rate in the coming years due to notable technological innovations. The market will also be encouraged by the rising demand for point of care administration and changing perspectives towards management medical conditions. For instance, several patients are opting for injectable drug delivery techniques, which is projected to drive the U.S. and EU-5 market for prefilled syringe small molecule.

The fact that usage of prefilled syringes does not require any assistance from trained medical staff, it has eliminated the need for hospitalization, which is benefitting the overall market to a large extent. The research report states that the U.S. and EU-5 prefilled syringes small molecule market will reach a valuation of US$17.1 bn by the end of 2024 from US$9.15 bn in 2015 as the market expands at a CAGR of 6.0 % to 8.0 % during the forecast period of 2016 and 2024.

us eu5 prefilled syringe small molecule market

Development of Biological Products to be an Emerging Trend

The overall market is projected to witness an introduction of a new drug class, which is poised to revolutionize the U.S. and EU-5 prefilled syringes small molecule market. Known as biological products, this drug class requires significantly high investments for both research and development. A score of stability issues and the higher monetary risks are expected to slow down the progress of the global market.

The new drug class is expected to introduce neurological small molecule drugs prefilled syringes, which will open up several lucrative opportunities for the new as well as existing players during the forecast period. For instance, Sandoz’s Glatopa (glatiramer acetate), which has been recently approved by the U.S. FDA has opened up several opportunities for the market in the neurological small molecule drug prefilled syringe segment.

Neurology Drugs Segment Shows Continued Growth due to Lack of Generic Drugs

On the basis of therapeutic class, the U.S. and EU-5 prefilled syringes small molecule has been segmented into cardiovascular drugs, analgesics, neurology drug, and adjuvants. The research report indicated that the neurology drugs segment held a dominant share of more than 44% in the U.S. and EU-5 prefilled syringes small molecule market. Analysts anticipate that the segment is estimated to retain a lead in the overall market during the forecast period as well due to the non-availability of several equivalent generic drugs. The most popularly sold brand in the neurology drugs segment is Copaxone. This segment is expected to play a major role in the growing revenue of the overall market in the coming few years.

The demand for cardiovascular and neurological small molecule prefilled syringes will remain high, thus proving to be a strategic growth driver for the market. This demand will be fueled by the high prevalence of emergency situations that require safe and accurate dose delivery often considered to be self-medication.

The report indicates that the cardiovascular small molecule prefilled syringe segment held a share of about 26.91% in the U.S. and EU-5 prefilled syringes small molecule market in 2015. Meanwhile, the share of preference adjuvant small molecules in prefilled syringe like dextrose and normal saline for flush stood at 7.16% of the U.S. and EU-5 prefilled syringes small molecule market in 2015. This segment was valued at US$655.4 mn in 2015. The demand for adjuvant small molecule prefilled syringe is expected to grow steadily in the coming years due to a strong presence of several local players and several distributors in the overall market.

The top players operating in the U.S. and EU-5 prefilled syringe small molecule market are Teva Pharmaceutical Industries Ltd., Mylan N.V., Hospira, Inc (Now Pfizer, Inc.), Becton, Fresenius Kabi, Sanofi, and Dickinson and Company.

U.S. and EU-5 Prefilled Syringe Small Molecule Market: Snapshot

The prefilled syringes small molecule market was valued around US$ 12.03 Bn in 2015, accounting for significant market share of the global prefilled syringes market and anticipated to grow at substantial growth rate over the forecast period. The primary objective of the report is to offer insights on the market dynamics that can influence growth of the prefilled syringe small molecule market in U.S. and EU-5 region over the forecast period. Insights on key trends, drivers, restraints, value forecasts and opportunities for companies operating in prefilled syringe small molecule market are presented in the report. 

U.S. and EU-5 Prefilled Syringe Small Molecule Market: Drivers and Trends

U.S. and EU-5 market for prefilled syringe small molecule is expected to witness significant growth rate in terms of value owing to the technology innovations in pertaining to prefilled syringes, increasing demand for point of care administration, and change in patient behavior - seeking rapid relief through injectable drug delivery contributes to growth of the U.S. and EU-5 market for prefilled syringe small molecule. To understand and assess opportunities in this market, the report offers market forecast on the basis of therapeutic class and regions. The report provides analysis of the U.S. and EU-5 market for prefilled syringe small molecule in terms of market value (US$ Mn) and volume. 

U.S. and EU-5 Prefilled Syringe Small Molecule Market: Segmentation

Based on therapeutic class, the market is segmented into neurology drug, cardiovascular drugs, analgesics, adjuvants. The neurology drugs segment held a significant share of the U.S. and EU-5 prefilled syringes small molecule market. The segment is anticipated to witness high growth during the forecast period. The high growth of the segment is attributed to the popularity of non-availability of many generic equivalent drugs. This segment consists of the most prominent best-selling brand such as Copaxone. Moreover, recently launched neurological small molecule prefilled syringe such as the Glatopa by Sandoz, throw light upon the fact that neurology small molecule drug prefilled syringe are a strong strategic growth driver in the prefilled syringe small molecule space and are here to stay. Both in the U.S. and EU-5, the trend is upwards for neurological and cardiovascular small molecule prefilled syringe owing to the need of availability in emergency situations for self-medication and safe and accurate dose delivery. 

U.S. and EU-5 Prefilled Syringe Small Molecule Market: Geographical Outlook

Geographically, the prefilled syringe small molecule market is studied for U.S. and EU-5 region. In the U.S., a key trend in the market has been a rise of generic equivalent availabilities and market exclusivity agreements. Although the generic equivalent availability is comparatively better in the U.S. compared to EU-5, most key players operating in this market believe that further increasing foray of small molecules owing to patent expiry and generic equivalents availability is the key to grow prefilled syringe small molecule market. 

The report includes a competitive landscape for prominent players in the prefilled syringe small molecule market. It has been included to provide a dashboard view of key companies operating in U.S. and EU-5 market for prefilled syringe small molecule. It also includes brief overview of prominent market strategies and SWOT analysis of the main players operational in the U.S. and EU-5 market for prefilled syringe small molecule. 

Key Players Mentioned in this Report are:

Key players in the U.S. and EU-5 market for prefilled syringe small molecule are Teva Pharmaceutical Industries Ltd., Hospira, Inc (Now Pfizer, Inc.), Mylan N.V., Fresenius Kabi, Becton, Dickinson and Company and Sanofi. 

The U.S. and EU-5 market for prefilled syringe small molecule has been segmented as follows:

U.S. and EU-5 Prefilled Syringe Small Molecule Market, by Therapeutic Class

  • Neurology
    • Glatiramer Acetate 
  • Cardiovascular Drugs
    • Atropine Sulfate
    • Furosemide 
    • Verapamil Hydrochloride
    • Amiodarone
    • Epinephrine/Adrenaline
    • Enoxaparin sodium
    • Fondaparinux Sodium
    • Nadroparin Calcium
    • Dalteparin
    • Ephedrine 
  • Analgesics
    • ketorolac Tromethamine
    • Morphine Sulphate
    • Dexamethasone Na Po4
    • Hydromorphone Hydrochloride 
  • Adjuvants
    • Water for Injection
    • NaCl 0.9%/Saline
    • HPMC
    • Sodium Hyaluronate
    • 25% Dextrose 
  • Others
    • Diphenhydramine
    • Midazolam
    • Lidocaine Hydrochloride
    • Penicillin
    • Metoclopramide
    • Ondansetron
    • Methotrexate
    • Fibrin Sealant
    • Gadobutrol


 
 
Back To Top